Research and Clinical Trials

The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.

LUNG CANCER

Trial Name Short Title Status Site Principal Investigator Contact
1 A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)

For more information, click here

 Canopy Recruiting University Malaya Medical Centre (UMMC) Prof Dr Liam Chong Kin +603-7949 2886
Pantai Hospital Kuala Lumpur (PHKL) Dr Mastura Md Yusof  +603-2296 0764 / 0800
Sarawak General Hospital (SGH) Dr Voon Pei Jye +608 227 6666 / 6035
2 A global randomized phase 3 open label study of REGN2810 (Anti PD-1 Antibody) versus platinum based chemotherapy in first line treatment of patient with advanced or metastatic PDL1 positive non small cell lung cancer REGENERON Recruiting Pusat Perubatan Universiti Malaya A/P Ho Gwo Fuang +603-79492423
3 A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib ELIOS Recruiting Hospital Pulau Pinang Dr Soo Hoo Hwoei Fen +604-2225767 / 2225762 / 2225766 / 2225586
Hospital Umum Sarawak Dr Voon Pei Jye +6082-276820
HTAA Prof How Soon Hin +609-5572922
4 A global, randomized, phase 3, open-label study of REGN2810 (antti-PD-1 antibody) versus Platinum based chemotherapy in first-line treatment of patients with advanced or metastatic PD-L1+ NSCLC EMPOWER Recruiting Hospital Umum Sarawak Dr Voon Pei Jye +6082-276820
HUKM Prof Dato’ Dr Fuad Ismail +603-9145 7588/7160
Hospital Pulau Pinang Dr Tan Ai Lian +604-2225767 / 2225762 / 2225766 / 2225586
5 A multi-country, multi-centre, observational, phase 4 , retrospective study to reveal the patient characteristics, disease burden, treatment patterns and patient journey of stage III non-small-cell lung cancer patients KINDLE Recruiting Hospital Kuala Lumpur Dr Malwinder +603-26155555 ext 1782 / 1783
6 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Celltrion Recruiting Pusat Perubatan Universiti Malaya Dr Adlinda +603-79492423

PROSTATE CANCER

Trial Name Short Title Status Site Pricipal Investigator Contact
1 AR-V7 Splice Variant in Asian Patients with Castration-Resistant Prostate Cancer (CRPC AR-V7 Recruiting Pusat Perubatan Universiti Malaya A/P Marniza Saad  +603-79492423
2 A Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer(1st line mets) MAGNITUDE Recruiting Pusat Perubatan Universiti Malaya A/P Marniza Saad +603-79492423
3 A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masinitib in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC) AB12003 Recruiting Hospital Pulau Pinang Dr Soo Hoo Hwoei Fen +604-2225767 / 2225762 / 2225766 / 2225586
Hospital Sultan Ismail Dr Lim Chun Sen +607-3565155
Pusat Perubatan Universiti Malaya Dr Adlinda +603-794

GASTROINTESTINAL CANCERS

Trial Name Short Title Status Site Pricipal Investigator Contact
1 Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Placebo Controlled Phase III Trial ASCOLT Recruiting Pusat Perubatan Universiti Malaya A/P Ho Gwo Fuang +603-79492423
Hospital Kuala Lumpur Dr Ros Suzanna +603-26155555 ext 1620 / 1144
2 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel with or without Ramucirumab (IMC-1121B) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive after First-Line Therapy with Platinum and Fluoropyrimidine Prostate Cancer Receiving Treatment with Primary Radiation Therapy. RAINBOW Asia Recruiting Hospital Umum Sarawak Dr Voon Pei Jye +6082-276820
Institut Kanser Negara Dr Wong Yoke Fui +603- 88925555, ext 4168
Hospital Kuala Lumpur Dr Ibtisam Binti Muhamad Nor +603-26155555 ext 1620 / 1144
Pusat Perubatan Universiti Malaya A/P Ho Gwo Fuang +603-79492423
3 A phase 3, global, multicentre, double blind randomized efficacy study of Zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first line treatment of subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma GLOW Recruiting Hospital Kuala Lumpur Dr Malwinder +603-26155555 ext 1782 / 1783
Hospital Pulau Pinang Dr Soo Hoo Hwoei Fen +604-2225767 / 2225762 / 2225766 / 2225586
Pusat Perubatan Universiti Malaya A/P Ho Gwo Fuang +603-79492423
4 A Phase III Randomized Double-blind Study of Pembrolizumab plus Best Supportive Care vs. Placebo plus Best Supportive Care as Second-Line Therapy in Asian Subjects with Previously Systematically Treated Advanced Hepatocellular Carcinoma PD KEYNOTE-394 Recruiting Pusat Perubatan Universiti Malaya A/P Ho Gwo Fuang +603-79492423

BREAST CANCER

Trial Name Short Title Status Site Pricipal Investigator Contact
1 An international randomized controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence. TARGIT-B: Pusat Perubatan Universiti Malaya Prof Nur Aishah
2 A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor positive/HER2-negative inoperable locally advanced or metastatic breast cancer – RIGHT Choice Study RIGHT CHOICE Recruiting Hospital Kuala Lumpur Dr Malwinder +603-26155555 ext 1782 / 1783
Hospital Sultan Ismail Dr Lim Chun Sen +607-3565155

BLADDER AND RENAL CANCERS

Trial Name Short Title Status Site Pricipal Investigator Contact
1 A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 Recruiting Pusat Perubatan Universiti Malaya Dr Adlinda +603-79492423
2 A prospective study using prostate-specific membrane antigen (PSMA) study as a potential vasculature prognostic marker for clear cell renal carcinoma (ccRCC) PSMA RCC Recruiting Nuclear Medicine Centre, Sunway Medical Centre 1. A/Prof Dr Tan Teik Hin

2. Dr Chew Ming Tsuey

 +603-7494-1017

The information above was last updated on 20 April 2019.

Source: http://clinicalresearch.my/